Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer

Prostate Cancer and Prostatic Diseases volume 10, pages 307–310 (2007)Cite this article

Abstract

Diagnosis of prostate cancer (PC) still remains critical as non-invasive screening with prostate specific-antigen (PSA) lacks to indicate malignancy of the prostate in some cases. Recent research has shown that clinically meaningful PC can develop in patients with a PSA value <4 ng/ml, frequently defined as upper limit of normal serum PSA levels. Furthermore, both morphological (computed tomography (CT), magnetic resonance imaging, transrectal ultrasound) and functional imaging with 18fluorodeoxyglucose positron emission tomography (FDG-PET) are associated with several limitations for primary diagnosis of PC. We report a case of an incidentally diagnosed PSA-negative PC by 18FDG PET/CT in a patient with a previous diagnosis of a hypopharyngeal cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dennis LK, Resnick MI . Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42: 247–252.

    Article  CAS  Google Scholar 

  2. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK . Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108–111.

    Article  CAS  Google Scholar 

  3. Ryan CJ, Small EJ . Progress in detection and treatment of prostate cancer. Curr Opin Oncol 2005; 17: 257–260.

    PubMed  Google Scholar 

  4. Garnick MB, Fair WR . Prostate cancer: emerging concepts. Part I. Ann Intern Med 1996; 125: 118–125.

    Article  CAS  Google Scholar 

  5. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scan for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162: 1322–1328.

    Article  CAS  Google Scholar 

  6. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30: 607–611.

    Article  CAS  Google Scholar 

  7. Tuzel E, Sevinc M, Obuz F, Sade M, Kirkali Z . Is magnetic resonance imaging necessary in staging of prostate cancer? Urologia Intis 1998; 61: 227–231.

    Article  CAS  Google Scholar 

  8. Barbieri A, Monica B, Sebastio N, Incarbone GP, Di Stefano C . Value and limitations of transrectal ultrasonography and computer tomography in preoperative staging of prostate carcinoma. Acta Bio-Med L Ateneo Parmense 1997; 68: 23–26.

    CAS  Google Scholar 

  9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME . A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S–93S.

    CAS  PubMed  Google Scholar 

  10. Langsteger W, Heinisch M, Fogelman I . The role of fluorodeoxyglucose, 18F-dihydrixyohenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006; 36: 73–92.

    Article  Google Scholar 

  11. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A . Positron emission tomography in urological oncology. J Urol 1998; 159: 347–356.

    Article  CAS  Google Scholar 

  12. Jana S, Blaufox MD . Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006; 36: 51–72.

    Article  Google Scholar 

  13. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M . Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31–35.

    Article  CAS  Google Scholar 

  14. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R . Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41: 425–429.

    Article  Google Scholar 

  15. von Mallek D, Backhaus B, Müller SC, Matthies A, Palmedo H, Jaeger U et al. Technische Grenzen des PET/CT mit 18FDG beim Adenokarzinom der Prostata. Aktuelle Urol 2006; 37: 218–221.

    Article  CAS  Google Scholar 

  16. Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM et al. Prognostic role of prostate-specific antigen and prostate volume fort the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005; 65: 300–305.

    Article  CAS  Google Scholar 

  17. Sindwhani P, Wilson CM . Prostatitis and serum prostate-specific antigen. Curr Urol Rep 2005; 6: 307–312.

    Article  Google Scholar 

  18. Kobayashi M, Kurokawa S, Tokue A . Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer subjects. Urol Int 2005; 74: 198–202.

    Article  CAS  Google Scholar 

  19. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004; 31: 317–324.

    Article  CAS  Google Scholar 

  20. Melchior SW, Fichtner J, Jones J, Gillitzer R, Hohenfellner M, Kreitner F et al. Changes in flurodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal. J Urol 1999; 161: 297.

    Article  Google Scholar 

  21. Oyama N, Akino H, Suzuki Y, Kanamura H, Sadato N, Yonekura Y et al. The increased accumulation of fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623–629.

    Article  CAS  Google Scholar 

  22. Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005; 7: 159–163.

    Article  Google Scholar 

  23. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 2005; 216 (Suppl): 64–81.

    Article  Google Scholar 

  24. Albrecht S, Buchegger F, Soloviev D, Zaidi H, Vee H, Khan HG et al. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34: 185–196.

    Article  Google Scholar 

  25. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176: 954–960.

    Article  CAS  Google Scholar 

  26. Schmid DT, John H, Zweifel R, Cservenyak T, Wetsera G, Goerres GW et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623–628.

    Article  Google Scholar 

  27. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 45–53.

    Article  Google Scholar 

  28. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006; 47: 1249–1254.

    CAS  PubMed  Google Scholar 

  29. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ . Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44: 331–335.

    PubMed  Google Scholar 

  30. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al. 18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33: 1387–1398.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University of Bonn, Bonn, Germany

    J Bucerius, H Ahmadzadehfar, A Y Joe, H Palmedo & H-J Biersack

  2. Department of Radiology, University of Bonn, Bonn, Germany

    N Hortling

  3. Gemeinschaftspraxis für Radiologie und Nuklearmedizin, Siegburg, Germany

    N Hortling

Authors
  1. J Bucerius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Ahmadzadehfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Hortling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Y Joe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Palmedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H-J Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Bucerius.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bucerius, J., Ahmadzadehfar, H., Hortling, N. et al. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer. Prostate Cancer Prostatic Dis 10, 307–310 (2007). https://doi.org/10.1038/sj.pcan.4500959

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500959

Keywords

This article is cited by

Search

Advanced search

Quick links